Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 12:16 PM
Ignite Modification Date:
2025-12-24 @ 12:16 PM
NCT ID:
NCT04981561
Brief Summary:
To evaluate the safety and tolerability of single ascending doses of GATE-251 in normal human volunteers
Detailed Description:
Single ascending dose (SAD), double-blind placebo-controlled study in normal human volunteers.
Secondary objectives:
To evaluate the pharmacokinetics (PK) and eeg biomarker of target engagement of GATE-251 following increasing single doses of GATE-251.
GATE-251 or Placebo: Dose/Mode of Administration: Single dose; oral
Study:
NCT04981561
Study Brief:
Protocol Section:
NCT04981561